CMSC 2022: Top Interviews and Key Takeaways

In early June 2022, the Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) was held completely in person for the first time since 2019. The meeting featured thousands of experts in the management of multiple sclerosis (MS), who came together in National Harbord, Marland, to discuss the latest advances, ongoing developments, and future direction of research. Additionally, the meeting featured the first Giants of Multiple Sclerosis awards ceremony, highlighting its inaugural class of pioneers and thought leaders.

The sessions and presentations at CMSC 2022 included topics such as the shortage of neurologists and the need for more MS specialists, a first-time analysis of neurofilament light chain and Bruton tyrosine kinase inhibition, women with MS and their use of social media, CD3 inhibition in MS, and more!

Swipe through the slideshow below to browse our interviews with experts on-site, and be sure to check back for ongoing coverage from the conference! 

Click here for more coverage of multiple sclerosis from NeurologyLive^®, or for more coverage of CMSC 2022, click here. 

REFERENCES
1. Teixiera-Poit S, Dalton P, Flach A, et al. An interprofessional student program providing early exposure to MS care and multidisciplinary teams. Presented at: CMSC Annual Meeting, 2022; June 1-4; National Harbor, MD.
2. Montalban X, Wolinsky JS, Arnold DL, et al. Safety and efficacy of evobrutinib, a Bruton Tyrosine kinase inhibitor, in relapsing multiple sclerosis over 2.5 years of the open-label extension to a phase 2 trial. Presented at: 2022 CMSC Annual Meeting; June 1-4; National Harbor, MD.
3. Bove R, Pasquarelli N, Gafarova M, Eighteen C, et al. Perceptions and discussions on the use of disease-modifying therapies during family planning in women with multiple sclerosis. Presented at: CMSC Annual Meeting; June 1-4, 2022; National Harbor, MD.
4. Dewey BE, Rjeily NB, Hulett C, et al. Spinal Cord Atrophy As a Marker of Disability Progression: Beyond Trial Data. Presented at: CMSC Annual Meeting; June 1-4, 2022; National Harbor, MD.
5. Chitnis T, Singhal T, Zurawski J, et al. Nasal anti-CD3 monoclonal antibody (foralumab) reduces PET microglial activation and blood inflammatory biomarkers in a patient with non-active secondary progressive MS. Presented at: CMSC Annual Meeting, 2022; June 1-4; National Harbor, MD.